5 results about "Mucosal adjuvant" patented technology

Provided are compositions, feeds, rations, drinking water and methods of use thereof for inducing protective immunity against or preventing Clostridium perfringens infection and / or necrotic enteritis in poultry, optionally as single dose vaccines. The composition comprises live virulent Clostridium perfringens (CP) and a mucosal adjuvant, such as cholera toxin (CT), which is for administered at or after hatch by for example oral delivery. The composition can be used with an immunomodulatory composition administered in ovo before hatching or a boost composition. The composition can be administered as a single dose.

Provided is a mucosal adjuvant comprising a compound represented by formula (I) A-L-B (in the formula, A represents a structure having TLR7 activity, L represents a linker, and B represents a structure having TLR2 activity) or a pharmacologically acceptable salt thereof.

This invention provides a subunit vaccine containing Mycoplasma pneumoniae HP14 / 30 fusion antigen and a mucosal adjuvant. The subunit vaccine comprises the Mycoplasma pneumoniae HP14 / 30 fusion antigen and a mucosal adjuvant in a mass ratio of 1-5:1. The HP14 / 30 fusion antigen is a recombinant protein co-expressed by chimeric fragments of the P1 and P30 proteins, with the amino acid sequence shown in SEQ ID NO:1. This vaccine is administered via mucosal routes such as nasal drops or oral inhalation. It efficiently induces respiratory mucosal-specific IgA and humoral IgG responses, significantly reduces pathogen load in the lungs, alleviates pathological damage to lung tissue, and does not induce enhanced respiratory disease (ERD). Its safety and protective efficacy are significantly superior to traditional inactivated vaccines and intramuscular vaccines. This invention fills the technological gap in human Mycoplasma pneumoniae subunit vaccines, is suitable for the prevention of Mycoplasma pneumoniae infection in children and adults, and has significant clinical application value.

The invention provides a human mycoplasma pneumoniae inactivated vaccine preparation and application thereof. The human mycoplasma pneumoniae inactivated vaccine preparation comprises inactivated mycoplasma pneumoniae thallus antigens and mucous membrane adjuvants. Wherein the mass ratio of the inactivated mycoplasma pneumoniae thallus antigen to the mucous membrane adjuvant is (2-5): 1. The inactivated vaccine preparation disclosed by the invention can induce an organism to generate mycoplasma pneumoniae specific IgG and IgA antibody titers after immunization in a nasal drop way, can protect the organism after mycoplasma pneumoniae infection, avoids weight loss and severe lung injury, fills the blank in the field of mycoplasma pneumoniae vaccines, and meets clinical requirements.

The disclosure provides compositions and methods for improving and enhancing systemic and mucosal vaccine immune responses. In particular, the disclosure provides mucosal adjuvant for vaccine delivery and methods of using the mucosal adjuvant in a vaccination regimen to induce sterilizing immunity in a vaccinated subject.